{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:16:56Z","timestamp":1788617816066,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An early molecular response is spectacularly predictive of outcome in chronic myeloid leukemia (CML) and early response landmarks may identify the high-risk patients likely to be benefit from an early therapy switch. In this study, we evaluated the most relevant cutoffs for early molecular response markers (BCR-ABL1 values at 3 months, log reduction and halving time between diagnosis and 3 months) in 476 first-line imatinib-treated Chinese patients with chronic phase CML. All outcomes were significantly superior for the 324 patients with 3-month BCR-ABL1 \u226410%, so did for the 270 patients with BCR-ABL1 &gt;0.61 log reduction. BCR-ABL1 halving time \u226422 days was identified for patients with the most favorable outcome. Moreover, the prognosis was significantly poorest for patients with both halving time &gt;44 days and BCR-ABL1 &gt;10%. Importantly, multivariate regression analysis demonstrated that a BCR-ABL1 log reduction calculated at 3 months of 0.61 was the only variable that significantly predicted for OS. Our results highlight the importance of rapid initial decline of BCR-ABL1 in predicting satisfactory outcome. Our data support the evidence that monitoring BCR-ABL1 values at an early time point could contribute to accurately assess response and ultimately guide clinical decisions regarding the timing of therapeutic intervention.<\/jats:p>","DOI":"10.1038\/s41408-018-0093-4","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T17:14:41Z","timestamp":1529082881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance"],"prefix":"10.1038","volume":"8","author":[{"given":"Jingru","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"93_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann, R., Hochhaus, A., Baccarani, M. & European, L. Chronic myeloid leukaemia. Lancet 370, 342\u2013350 (2007).","journal-title":"Lancet"},{"key":"93_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour, E. et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123, 494\u2013500 (2014).","journal-title":"Blood"},{"key":"93_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-013-1470-1","volume":"99","author":"S Fujisawa","year":"2014","unstructured":"Fujisawa, S. et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up. Int. J. Hematol. 99, 141\u2013153 (2014).","journal-title":"Int. J. Hematol."},{"key":"93_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes, T. P. et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123, 1353\u20131360 (2014).","journal-title":"Blood"},{"key":"93_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin, D. et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30, 232\u2013238 (2012).","journal-title":"J. Clin. Oncol."},{"key":"93_CR6","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein, B. et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26, 2096\u20132102 (2012).","journal-title":"Leukemia"},{"key":"93_CR7","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford, S. et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J. Clin. Oncol. 30, 4323\u20134329 (2012).","journal-title":"J. Clin. Oncol."},{"key":"93_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872\u2013884 (2013).","journal-title":"Blood"},{"key":"93_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.leukres.2015.01.011","volume":"39","author":"SE Lee","year":"2015","unstructured":"Lee, S. E. et al. Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia. Leuk. Res. 39, 411\u2013418 (2015).","journal-title":"Leuk. Res."},{"key":"93_CR10","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein, B. et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28, 1988\u20131992 (2014).","journal-title":"Leukemia"},{"key":"93_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford, S. et al. Prognosis for patients with CML and 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124, 511\u2013518 (2014).","journal-title":"Blood"},{"key":"93_CR12","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"93_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054\u20131061 (2009).","journal-title":"Leukemia"},{"key":"93_CR14","first-page":"395","volume":"7","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y. & Qian, S. X. Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients. Onco. Targets Ther. 7, 395\u2013404 (2014).","journal-title":"Onco. Targets Ther."},{"key":"93_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/aps.2010.79","volume":"31","author":"QB Li","year":"2010","unstructured":"Li, Q. B. et al. Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacol. Sin. 31, 999\u20131004 (2010).","journal-title":"Acta Pharmacol. Sin."},{"key":"93_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","volume":"30","author":"YZ Qin","year":"2008","unstructured":"Qin, Y. Z. et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int. J. Lab. Hematol. 30, 317\u2013323 (2008).","journal-title":"Int. J. Lab. Hematol."},{"key":"93_CR17","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain, P. et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121, 4867\u20134874 (2013).","journal-title":"Blood"},{"key":"93_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama, N. et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am. J. Hematol. 90, 282\u2013287 (2015).","journal-title":"Am. J. Hematol."},{"issue":"Suppl","key":"93_CR19","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.clml.2016.03.008","volume":"16","author":"C Fava","year":"2016","unstructured":"Fava, C. et al. Early BCR-ABL1 reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor. Clin. Lymphoma Myeloma Leuk. 16(Suppl), S96\u2013S100 (2016).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"93_CR20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2013.9048","volume":"9","author":"WH El-Metnawy","year":"2013","unstructured":"El-Metnawy, W. H. et al. Predictive value of pretreatment BCR-ABL(IS) transcript level on response to imatinib therapy in Egyptian patients with chronic phase chronic myeloid leukemia (CPCML). Int. J. Biomed. Sci. 9, 48\u201353 (2013).","journal-title":"Int. J. Biomed. Sci."},{"key":"93_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106250","volume":"9","author":"S Huet","year":"2014","unstructured":"Huet, S. et al. Major molecular response achievement in CML patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended. PLoS ONE 9, e106250 (2014).","journal-title":"PLoS ONE"},{"key":"93_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.beha.2016.10.006","volume":"29","author":"S Branford","year":"2016","unstructured":"Branford, S. Monitoring and defining early response: where to draw the line? Best Pract. Res. Clin. Haematol. 29, 284\u2013294 (2016).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"93_CR23","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson, R. A. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022\u20134028 (2008).","journal-title":"Blood"},{"key":"93_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171041","volume":"12","author":"M El Missiry","year":"2017","unstructured":"El Missiry, M. et al. Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia. PLoS ONE 12, e0171041 (2017).","journal-title":"PLoS ONE"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0093-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T14:22:58Z","timestamp":1720362178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0093-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0093-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"20 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"61"}}